Researchers from Boston University School of Medicine have demonstrated that certain T cells require input from monocytes in order to maintain their pro-inflammatory response in people with Type 2 diabetes….
Read More »Diabetes In Control
Fitness Consultations in Care of Type 2 Patients Improves Outcomes
Increasing physical activity is a cornerstone in the treatment of Type 2 diabetes and in general practice it is a challenge to achieve long-term adherence to this lifestyle change….
Read More »Finger Length Linked to Prostate Cancer Risk
Men with long index fingers have a lower risk of prostate cancer….
Read More »Metformin’s Effect on Mortality in Patients with Heart Failure and Type 2 Diabetes
Type 2 diabetes mellitus plus chronic heart failure is a common but lethal combination and therapeutic options are limited. Metformin is perceived as being relatively contraindicated in this context….
Read More »Off. On. Off. On. The Circuitry of Insulin-Releasing Cells
Researchers at the Johns Hopkins University School of Medicine have teased out how these cells interpret incoming signals and find that three proteins relay signals similar to an electrical circuit….
Read More »Air Pollution Raises Risk of Diabetes in Kids
While poor diet and lack of exercise are thought to be the leading causes of diabetes, exposure to polluted air early in life can also lead to the disease….
Read More »Letter from the Editor: Happy New Year!
Happy New Year to all of you from all of us here at Diabetes In Control. This is the time of year that most of our patients get back to taking care of themselves. They have put away the decorations and wrapping paper, finished off the holiday leftovers and are …
Read More »Editor’s Note: Happy New Year!
As we welcome the New Year we want to thank all of you who have been able to use the information from our Diabetes Clinical Mastery Series to improve your knowledge. Last week I received a note from a physician in Huntington, WV, that makes me feel that the work …
Read More »New Product: Amturnide
Amturnide (aliskiren, amlodipine and hydrochlorothiazide) from Novartis is a medication in tablet form for the treatment of high blood pressure. Amturnide combines the direct renin inhibitor Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).
Read More »GoMeals
sanofi-aventis U.S., LLC Free iOS/Android GoMeals® was developed to help patients make healthy lifestyle choices at home or on the go. The app includes tools for eating healthy, staying active, and tracking blood glucose levels….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.